Verastem, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VSTM Nasdaq 2830 www.verastem.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Verastem, Inc.

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 12th, 2026 2:01 pm
Revolution Medicines stock surges over 20% on potential AbbVie acquisition - Jan 7th, 2026 1:33 pm
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Dec 29th, 2025 2:01 pm
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - Dec 28th, 2025 10:46 am
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth - Dec 15th, 2025 2:01 pm
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company - Dec 15th, 2025 7:20 am
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference - Nov 25th, 2025 5:30 am
TEM Continues to Strengthen Its Genomics Leadership With New Products - Nov 14th, 2025 5:57 am
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants - Nov 13th, 2025 10:41 pm
Verastem Oncology Announces Proposed Public Offering of Common Stock - Nov 13th, 2025 2:07 pm
Verastem Oncology to Present at Upcoming Investor Conferences - Nov 5th, 2025 5:30 am
Verastem (VSTM): Rapid 55.7% Revenue Growth Forecast Challenges Persistent Unprofitability Narrative - Nov 4th, 2025 7:16 pm
Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... - Nov 4th, 2025 2:02 pm
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates - Nov 4th, 2025 6:40 am
Verastem: Q3 Earnings Snapshot - Nov 4th, 2025 5:40 am
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates - Nov 4th, 2025 5:30 am
Verastem (VSTM) Upgraded to Buy: Here's Why - Nov 3rd, 2025 10:00 am
Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment - Oct 29th, 2025 9:57 am
Can Verastem's (VSTM) Early KRAS Results Redefine Its Position in Oncology Innovation? - Oct 24th, 2025 7:09 pm
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors - Oct 23rd, 2025 2:01 pm